Treatments in Endocrinology

, Volume 4, Issue 5, pp 263–277 | Cite as

Antiresorptive Therapy for the Prevention of Postmenopausal Osteoporosis

When Should Treatment Begin?
Current Opinion

Abstract

Osteoporosis is a condition associated with decreased bone strength and an increased fracture risk. It may be defined based on bone mineral density (BMD) with a T-score at the hip or spine of less than −2.5 standard deviations in young healthy individuals or from an osteoporotic fracture (i.e. a fracture occurring after low-energy trauma or no apparent trauma).

Risk factors predisposing to fractures include: increasing age; female gender; low BMD; a prior fragility fracture; a family history of fragility fractures; low bodyweight; lack of estrogen in women (i.e. post menopause); corticosteroid use; smoking; a number of diseases; deficiency in calcium and vitamin D; an increased risk of falls (i.e. impaired vision); immobilization; and Caucasian race. The more risk factors that are present the higher the risk of fractures over the following 10 years. The need to initiate preventive therapy with anti-osteoporotic treatment increases steeply with the absolute fracture risk.

Indications for referral for dual energy x-ray absorptiometry measurement of BMD include: age >65 years; age <65 years in postmenopausal women with any of the risk factors already mentioned; premature menopause (<45 years); prolonged amenorrhea (>1 year) in younger women; fragility fractures; and diseases or conditions known to lead to osteoporosis.

Antiresorptive therapies include calcium plus vitamin D, bisphosphonates (alendronate, etidronate, risedronate, ibandronate), selective estrogen receptor modulators (raloxifene), hormone replacement therapy, and calcitonin.

Guidelines from several countries on when to initiate antiresorptive therapy state that therapy may be started in patients with a prior fragility fracture (some guidelines state that in this situation no BMD measurements are necessary) or in patients with a T-score of less than −2.5 (some guidelines state that additional risk factors need to be present in this situation). Some guidelines state that antiresorptive therapy may be initiated in patients with a T-score in the osteopenic range (from −1 to −2.5, i.e. not frank osteoporosis) in the presence of other risk factors.

The cost effectiveness of antiresorptive therapy increases with the absolute fracture risk. In some scenarios, treatment with bisphosphonates may be cost effective in a 50-year-old woman with an absolute hip fracture risk of ≥ 1.1% over the next 10 years.

References

  1. 1.
    Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646–50CrossRefGoogle Scholar
  2. 2.
    Alexeeva L, Burkhardt P, Christiansen C, et al. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group [WHO technical report series no. 843]. Geneva, WHO: 1994Google Scholar
  3. 3.
    Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 1994; 4: 368–81PubMedCrossRefGoogle Scholar
  4. 4.
    NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785–95CrossRefGoogle Scholar
  5. 5.
    Faulkner KG, Orwoll E. Implications in the use of T-scores for the diagnosis of osteoporosis in men. J Clin Densitom 2002; 5: 87–93PubMedCrossRefGoogle Scholar
  6. 6.
    Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int 2005; 16: 134–41PubMedCrossRefGoogle Scholar
  7. 7.
    Kelly TJ. Bone mineral density reference database for American men and women [abstract]. J Bone Miner Res 1990; 5Suppl. 2: S249Google Scholar
  8. 8.
    Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005; 16: 581–9PubMedCrossRefGoogle Scholar
  9. 9.
    Dorland’s Illustrated Medical Dictionary. Philadelphia (PA): WB Saunders Co., 1985Google Scholar
  10. 10.
    Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999; 353: 571–80PubMedCrossRefGoogle Scholar
  11. 11.
    Boldsen JL, Jeune B. Distribution of age at menopause in two Danish samples. Hum Biol 1990; 62: 291–300PubMedGoogle Scholar
  12. 12.
    Flint M. Is there a secular trend in age of menopause? Maturitas 1978; 1: 133–9PubMedCrossRefGoogle Scholar
  13. 13.
    Dawson-Hughes B, Gold DT, Rodbard HW, et al. Physician’s guide to prevention and treatment of osteoporosis. Washington (DC): National Osteoporosis Foundation, 2003Google Scholar
  14. 14.
    Mundy GR, Chen D, Oyajobi BO. Bone remodeling. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of bone metabolism. Washington (DC): ASBMR, 2003: 46–58Google Scholar
  15. 15.
    Eriksen EF, Vesterby A, Kassem M, et al. Bone remodeling and bone structure. In: Mundy GR, Martin TJ, editors. Physiology and pharmacology of bone. Berlin: Springer Verlag, 1993: 67–109CrossRefGoogle Scholar
  16. 16.
    Vestergaard P, Mosekilde L, Brixen K. Antiresorptive therapy in osteoporosis. Ugeskr Laeger 2005; 167: 883–7PubMedGoogle Scholar
  17. 17.
    Blake GM, Wahner HW, Fogelman I. The evaluation of osteoporosis: dual energy x-ray absorptiometry and ultrasound in clinical practice. London: Martin Dunitz, 1999Google Scholar
  18. 18.
    Leib ES, Lewiecki EM, Brinkley N, et al. Official positions of the International Society for Clinical Densitometry. J Clin Densitom 2004; 7: 1–6PubMedCrossRefGoogle Scholar
  19. 19.
    Riggs BL, Melton III LJ. Evidence for two distinct syndromes of involutional osteoporosis. Am J Med 1983; 75: 899–901PubMedCrossRefGoogle Scholar
  20. 20.
    Vestergaard P, Krogh K, Rejnmark L, et al. Fracture rates and risk factors for fractures in patients with spinal cord injury. Spinal Cord 1998; 36: 790–6PubMedCrossRefGoogle Scholar
  21. 21.
    Black DM, Cummings SR, Kerpf DB, et al. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535–41PubMedCrossRefGoogle Scholar
  22. 22.
    Roy DK, O’Neill TW, Finn JD, et al. Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 2003; 14: 19–26PubMedCrossRefGoogle Scholar
  23. 23.
    Rea JA, Chen MB, Li J, et al. Morphometric x-ray absorptiometry and morphometric radiography of the spine: a comparison of prevalent vertebral deformity identification. J Bone Miner Res 2000; 15: 564–74PubMedCrossRefGoogle Scholar
  24. 24.
    Greenspan SL, von Stetten E, Emond SK, et al. Instant vertebral assessment: a noninvasive dual x-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis. J Clin Densitom 2001; 4: 373–80PubMedCrossRefGoogle Scholar
  25. 25.
    Watts NB, Josse RG, Hamdy RC, et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2003; 88: 542–9PubMedCrossRefGoogle Scholar
  26. 26.
    Vestergaard P, Mosekilde L. Fracture risk associated with smoking: a meta-analysis. J Intern Med 2003; 254: 572–83PubMedCrossRefGoogle Scholar
  27. 27.
    Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk: a meta-analysis. Thyroid 2003; 13: 585–93PubMedCrossRefGoogle Scholar
  28. 28.
    Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15: 721–39PubMedCrossRefGoogle Scholar
  29. 29.
    Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. Bone 2004; 35: 1029–37PubMedCrossRefGoogle Scholar
  30. 30.
    Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with systemic and topical corticosteroids. J Intern Med 2005; 257: 374–84PubMedCrossRefGoogle Scholar
  31. 31.
    Vestergaard P. Fracture risk secondary to disease [thesis]. Aarhus: Faellestrykkeriet for Sundhedsvidenskab, 2003Google Scholar
  32. 32.
    Stein E, Shane E. Secondary osteoporosis. Endocrinol Metab Clin North Am 2003; 32: 115–34PubMedCrossRefGoogle Scholar
  33. 33.
    van Staa TP, Abenhaim L, Cooper C, et al. Public health impact of adverse bone effects of oral corticosteroids. Br J Clin Pharmacol 2001; 51: 601–7PubMedCrossRefGoogle Scholar
  34. 34.
    Prevention and management of osteoporosis. WHO technical report series no. 921. Geneva: WHO, 2003Google Scholar
  35. 35.
    Wilson JNG, Jungner F. Principles and practice of screening for disease [public health papers no. 34]. Geneva: WHO, 1968Google Scholar
  36. 36.
    Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12: 24–35PubMedCrossRefGoogle Scholar
  37. 37.
    Cranney A, Guyatt G, Krolicki N, et al. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 2001; 12: 140–51PubMedCrossRefGoogle Scholar
  38. 38.
    Cranney A, Tugwell P, Wells G, et al. Meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 496–507PubMedCrossRefGoogle Scholar
  39. 39.
    Cranney A, Wells G, Willan A, et al. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23: 508–16PubMedCrossRefGoogle Scholar
  40. 40.
    Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 540–51PubMedCrossRefGoogle Scholar
  41. 41.
    Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 524–8PubMedCrossRefGoogle Scholar
  42. 42.
    Cranney A, Tugwell P, Adachi J, et al. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 517–23PubMedCrossRefGoogle Scholar
  43. 43.
    Cranney A, Guyatt G, Griffith L, et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570–8PubMedCrossRefGoogle Scholar
  44. 44.
    Papadimitropoulos E, Wells G, Shea B, et al. Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23: 560–9PubMedCrossRefGoogle Scholar
  45. 45.
    Shea B, Wells G, Cranney A, et al. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002; 23: 552–9PubMedCrossRefGoogle Scholar
  46. 46.
    Wells G, Tugwell P, Shea B, et al. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23: 529–39PubMedCrossRefGoogle Scholar
  47. 47.
    Osteoporosis in the European Community. Action plan (a report of the European Osteoporosis Consultation Panel, IOF-EC-Policy4, Nov 03). Brussels: European Community, 2003Google Scholar
  48. 48.
    Cheung AM, Feig DS, Kapral M, et al. Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ 2004; 170: 1665–7PubMedCrossRefGoogle Scholar
  49. 49.
    Changes in the criteria for reimbursement of bisphosphonates or raloxifene for preventing osteoporosis [abstract]. Ugeskr Laeger 2000; 162: 6512Google Scholar
  50. 50.
    Fuleihan GE, Baddoura R, Awada H, et al. Practice guidelines on the use of bone mineral density measurements who to test? What measures to use? When to treat? A Consensus report from the Middle East Densitometry Workshop. Leb Med J 2002; 50: 89–104Google Scholar
  51. 51.
    Raef H, Frayha HH, El-Shaker M, et al. Recommendations for the diagnosis and management of osteoporosis: a local perspective. Ann Saudi Med 2004; 24: 242–52PubMedGoogle Scholar
  52. 52.
    North American Menopause Society. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause 2002; 9: 84–101Google Scholar
  53. 53.
    Jorgensen JT, Andersen PB, Rosholm A, et al. Digital x-ray radiogrammetry: a new appendicular bone densitometric method with high precision. Clin Physiol 2000; 20: 330–5PubMedCrossRefGoogle Scholar
  54. 54.
    Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15: 1526–36PubMedCrossRefGoogle Scholar
  55. 55.
    Vestergaard P, Hermann AP, Gram J, et al. Evaluation of methods for prediction of bone mineral density by clinical and biochemical variables in perimenopausal women. Maturitas 2001; 40: 211–20PubMedCrossRefGoogle Scholar
  56. 56.
    Sen SS, Rives VP, Messina OD, et al. A risk assessment tool (OsteoRisk) for identifying Latin American women with osteoporosis. J Gen Intern Med 2005; 20: 245–50PubMedCrossRefGoogle Scholar
  57. 57.
    Cadarette SM, Jaglal SB, Murray TM, et al. Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA 2001; 286: 57–63PubMedCrossRefGoogle Scholar
  58. 58.
    Black DM, Steinbuch M, Palermo L, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 2001; 12: 519–28PubMedCrossRefGoogle Scholar
  59. 59.
    Wallace LS, Ballard JE, Holiday D, et al. Evaluation of decision rules for identifying low bone density in postmenopausal African-American women. J Natl Med Assoc 2004; 96: 290–6PubMedGoogle Scholar
  60. 60.
    Koh LK, Sedrine WB, Torralba TP, et al. A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporos Int 2001; 12: 699–705PubMedCrossRefGoogle Scholar
  61. 61.
    Geusens P, Hochberg MC, van der Voort DJ, et al. Performance of risk indices for identifying low bone density in postmenopausal women. Mayo Clin Proc 2002; 77: 629–37PubMedCrossRefGoogle Scholar
  62. 62.
    Clinical practice guidelines for the diagnosis and management of osteoporosis: Scientific Advisory Board, Osteoporosis Society of Canada. CMAJ 1996; 155: 1113–33Google Scholar
  63. 63.
    Kanis JA, Torgerson D, Cooper C. Comparison of the European and USA practice guidelines for osteoporosis. Trends Endocrinol Metab 2000; 11: 28–32PubMedCrossRefGoogle Scholar
  64. 64.
    Kleerekoper M. Treatment of osteoporosis. Clin Obstet Gynecol 2004; 47: 413–23PubMedCrossRefGoogle Scholar
  65. 65.
    Compston JE, Papapoulos SE, Blanchard JF. Report on osteoporosis in the European community: current status and recommendations for the future. Osteoporos Int 1998; 8: 531–4PubMedCrossRefGoogle Scholar
  66. 66.
    Eastell R, Reid DM, Compston J, et al. A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998; 244: 271–92PubMedCrossRefGoogle Scholar
  67. 67.
    Eastell R, Reid DM, Compston J, et al. Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action? QJM 2001; 94: 575–97PubMedCrossRefGoogle Scholar
  68. 68.
    Genant HK, Cooper C, Poor G, et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 1999; 10: 259–64PubMedCrossRefGoogle Scholar
  69. 69.
    Meunier PJ, Delmas PD, Eastell R, et al. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin Ther 1999; 21: 1025–44PubMedCrossRefGoogle Scholar
  70. 70.
    Morii H, Genant HK. Statement on the diagnosis and management of osteoporosis from the Consensus Development Conference at the Second International Conference on Osteoporosis, Osaka 1997. J Bone Miner Metab 1998; 16: 206–14CrossRefGoogle Scholar
  71. 71.
    Reginster JY. Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities. J Intern Med 2004; 255: 615–28PubMedCrossRefGoogle Scholar
  72. 72.
    Vestergaard P, Rejnmark L, Mosekilde L. Hip fracture prevention: cost-effective strategies. Pharmacoeconomics 2001; 19: 449–68PubMedCrossRefGoogle Scholar
  73. 73.
    Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004; 164: 1108–12PubMedCrossRefGoogle Scholar
  74. 74.
    Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254–9PubMedCrossRefGoogle Scholar
  75. 75.
    Phillips S, Fox N, Jacobs J, et al. The direct medical costs of osteoporosis for American women aged 45 and older, 1986. Bone 1988; 9: 271–9PubMedCrossRefGoogle Scholar
  76. 76.
    Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip fractures. Lancet 1993; 341: 11–3PubMedCrossRefGoogle Scholar
  77. 77.
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33PubMedCrossRefGoogle Scholar
  78. 78.
    Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003; 290: 1729–38PubMedCrossRefGoogle Scholar
  79. 79.
    The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–12CrossRefGoogle Scholar
  80. 80.
    International Osteoporosis Foundation. Evidence-based guidelines currently available [online]. Available from URL: http://www.osteofound.org/health_professionals/ guidelines/guidelines_list.html [Accessed 2005 May 1]Google Scholar
  81. 81.
    Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women: Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332: 767–73PubMedCrossRefGoogle Scholar
  82. 82.
    Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077–82PubMedCrossRefGoogle Scholar
  83. 83.
    Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporosis Int 1999; 8: 468–89CrossRefGoogle Scholar
  84. 84.
    Heaney RP, Zizic TM, Fogelman I, et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 2002; 13: 501–5PubMedCrossRefGoogle Scholar
  85. 85.
    Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87: 3609–17PubMedCrossRefGoogle Scholar
  86. 86.
    McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333–40PubMedCrossRefGoogle Scholar
  87. 87.
    Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19: 893–9PubMedCrossRefGoogle Scholar
  88. 88.
    Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35: 375–82PubMedCrossRefGoogle Scholar
  89. 89.
    Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005 Jul; 16(7): 737–42PubMedCrossRefGoogle Scholar
  90. 90.
    Kanis JA, Johansson H, Oden A, et al. A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporos Int 2005 Jul; 16(7): 799–804PubMedCrossRefGoogle Scholar
  91. 91.
    Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005 Feb; 16(2): 155–62PubMedCrossRefGoogle Scholar
  92. 92.
    Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D, and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637–42PubMedCrossRefGoogle Scholar
  93. 93.
    Chapuy MC, Arlot ME, Delmas PD, et al. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994; 308: 1081–2PubMedCrossRefGoogle Scholar
  94. 94.
    Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res 2004; 19: 370–8PubMedCrossRefGoogle Scholar
  95. 95.
    Trivedi TP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double-blind controlled trial. BMJ 2003; 326: 469–75PubMedCrossRefGoogle Scholar
  96. 96.
    Heikinheimo RJ, Inkovaara JA, Harju EJ, et al. Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 1992; 51: 105–10PubMedCrossRefGoogle Scholar
  97. 97.
    Lips P, Graafmans WC, Ooms ME, et al. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 1996; 124: 400–6PubMedGoogle Scholar
  98. 98.
    Meyer HE, Smedshaug GB, Kvaavik E, et al. Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. J Bone Miner Res 2002; 17: 709–15PubMedCrossRefGoogle Scholar
  99. 99.
    Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670–6PubMedCrossRefGoogle Scholar
  100. 100.
    Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000; (2): CD000952Google Scholar
  101. 101.
    Vestergaard P, Mosekilde L. Economic cost of different intervention regimens to prevent hip fractures. Ugeskr Laeger 1999; 161: 4400–5PubMedGoogle Scholar
  102. 102.
    Torgerson DJ, Kanis JA. Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. QJM 1995; 88: 135–9PubMedGoogle Scholar
  103. 103.
    Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium OR vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005; 365: 1621–8PubMedCrossRefGoogle Scholar
  104. 104.
    Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005; 330: 1003–9PubMedCrossRefGoogle Scholar
  105. 105.
    Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996; 276: 1389–96Google Scholar
  106. 106.
    Mosekilde L, Beck-Nielsen H, Sorensen OH, et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women: results of the Danish Osteoporosis Prevention Study. Maturitas 2000; 36: 181–93PubMedCrossRefGoogle Scholar
  107. 107.
    EMEA. EMEA public statement on recent publications regarding hormone replacement therapy [online]. Available from URL: http://www.emea.eu.int/pdfs/ human/press/pus/3306503en.pdf [Accessed 2005 May 1]Google Scholar
  108. 108.
    Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–27PubMedCrossRefGoogle Scholar
  109. 109.
    Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360: 942–4PubMedCrossRefGoogle Scholar
  110. 110.
    Brecht JG, Kruse HP, Mohrke W, et al. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharmacol Res 2004; 24: 1–10PubMedGoogle Scholar
  111. 111.
    Brumsen C, Papapoulos SE, Lips P, et al. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 2002; 17: 1057–64PubMedCrossRefGoogle Scholar
  112. 112.
    Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653–61PubMedCrossRefGoogle Scholar
  113. 113.
    Ringe JD, Dorst A, Faber H, et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003; 14: 801–7PubMedCrossRefGoogle Scholar
  114. 114.
    Liberman UA, Weiss SR, Broil J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: the Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437–43PubMedCrossRefGoogle Scholar
  115. 115.
    Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 1999; 9: 461–8PubMedCrossRefGoogle Scholar
  116. 116.
    Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337: 382–7PubMedCrossRefGoogle Scholar
  117. 117.
    Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44: 202–11PubMedCrossRefGoogle Scholar
  118. 118.
    Geusens P, Dequeker J, Vanhoof J, et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment: a double-blind, randomised placebo-controlled study. Ann Rheum Dis 1998; 57: 724–7PubMedCrossRefGoogle Scholar
  119. 119.
    Jenkins EA, Walker-Bone KE, Wood A, et al. The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. Scand J Rheumatol 1999; 28: 152–6PubMedCrossRefGoogle Scholar
  120. 120.
    Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-induced Osteoporosis Treatment Study. J Bone Miner Res 2000; 15: 1006–13PubMedCrossRefGoogle Scholar
  121. 121.
    Roux C, Oriente P, Laan R, et al. Randomised trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss: Ciblos Study Group. J Clin Endocrinol Metab 1998; 83: 1128–33PubMedCrossRefGoogle Scholar
  122. 122.
    Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 292–9PubMedCrossRefGoogle Scholar
  123. 123.
    Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003; 18: 919–24PubMedCrossRefGoogle Scholar
  124. 124.
    Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67: 277–85PubMedCrossRefGoogle Scholar
  125. 125.
    Amin S, Lavalley MP, Simms RW, et al. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002; 17: 1512–26PubMedCrossRefGoogle Scholar
  126. 126.
    Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003; 349: 457–63PubMedCrossRefGoogle Scholar
  127. 127.
    Jönsson L, Borgström F, Zethraeus N. Omkostningseffektivitet ved alendronatbe-handling af osteoporose i Danmark. Ugeskr Laeger 2003; 165: 4112–6PubMedGoogle Scholar
  128. 128.
    Chesnut III CH, Silverman S, Andriano KA, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. PROOF Study Group. Am J Med 2000; 109: 267–76PubMedCrossRefGoogle Scholar
  129. 129.
    Cranney A, Welch V, Adachi JD, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000; (2): CD001983Google Scholar
  130. 130.
    Vestergaard P, Hermann AP, Gram J, et al. Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. Maturitas 1997; 28: 137–45PubMedCrossRefGoogle Scholar
  131. 131.
    Christensen PM, Brixen K, Gyrd-Hansen D, et al. Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol 2005; 96: 387–96PubMedCrossRefGoogle Scholar
  132. 132.
    Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 2005; 17: 462–6PubMedGoogle Scholar
  133. 133.
    Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003; 5: 859–62PubMedGoogle Scholar
  134. 134.
    Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167: S1–34PubMedGoogle Scholar
  135. 135.
    Adler RA, Hochberg MC. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 2003; 163: 2619–24PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.The Osteoporosis Clinic Aarhus AmtssygehusAarhus CDenmark

Personalised recommendations